Use of Radium-223 Dichloride in Patients With Osteonecrosis of the Jaw Induced by Zoledronic Acid: Report of Two Cases

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2019.03.002
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Treatment of Castration-Resistant Prostate Cancer and Bone Metastases With Radium-223 Dichloride

International Journal of Urological Nursing
UrologyNursingNephrology
2014English

Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients After Treatment With Zoledronic Acid or Denosumab: A Retrospective Cohort Study

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
2015English

A Peroxisome Proliferator-Activated Receptor Gamma (PPARG) Polymorphism Is Associated With Zoledronic Acid-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients: Analysis by DMET Microarray Profiling

British Journal of Haematology
Hematology
2011English

Osteonecrosis of the Jaw Induced by Clodronate, an Alkylbiphosphonate: Case Report and Literature Review

European Journal of Clinical Pharmacology
MedicinePharmacology
2010English

Effect of Radium-223 Dichloride (Ra-223) on Hospitalisation: An Analysis From the Phase 3 Randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) Trial

European Journal of Cancer
Cancer ResearchOncology
2017English

Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Conditionally Pathogenic Microorganisms in Patients With Bisphosphonate Jaw Osteonecrosis

Stomatologiya
MedicineDentistry
2016English

The Contemporary Use of Radium-223 in Metastatic Castration Resistant Prostate Cancer

Clinical Genitourinary Cancer
OncologyUrology
2018English

Radium-223 for the Treatment of Patients With Castration-Resistant Prostate Cancer With Bone Metastases

Medical Council
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy